Please login to the form below
25
Revenue 2017CSL
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of CSL's 2013 sales performance.
EC approves first gene therapy for adults with haemophilia B
The European Commission (EC) has granted conditional marketing authorisation to CSL’s Hemgenix (etranacogene dezaparvovec) as the first gene therapy for haemophilia B. ... Dr Bill Mezzanotte, CSL’s head of research and development and chief medical
Pfizer announces positive phase 3 results for haemophilia B gene therapy
In November last year, the US Food and Drug Administration approved CSL Behring’s Hemgenix (etranacogene dezaparvovec) as the first gene therapy for adult patients with haemophilia B.
Influenza – the risk to vulnerable populations
and Fluzone High-Dose Quadrivalent (Influenza Vaccine) by Sanofi Pasteur and Fluad Quadrivalent(Influenza Vaccine, Adjuvanted) by CSL Seqirus UK. ... At CSL Seqirus, we support the public health benefit of an EIV category recommendation for older adults.
FDA approves first gene therapy for adults with haemophilia B
CSL’s Hemgenix allowed patients to produce mean factor IX activity of 39% at six months. ... The US Food and Drug Administration (FDA) has approved CSL Behring’s (CSL) Hemgenix (etranacogene dezaparvovec) as the first gene therapy for adult patients
Customers, content and change
variant. From personalisation to hyper-personalisation. Another perspective on customer engagement was provided by Lutz Bonacker, senior vice president and general manager for Commercial Operations Europe at CSL Behring.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- FDA external report recommends actions to address US opioid crisis
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Congress is in session – how companies are boosting their impact and engagement
- AstraZeneca announces major expansion of Canadian research footprint
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Anthem PR
With a rare strength in media and influencer relations, Anthem’s award-winning team offers a fresh approach to health PR...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
